Redhill Biopharma Ltd. (NASDAQ:RDHL)‘s stock had its “buy” rating restated by equities research analysts at Roth Capital in a note issued to investors on Wednesday. They currently have a $27.00 price target on the biotechnology company’s stock. Roth Capital’s price target would suggest a potential upside of 172.73% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $36.00 target price (up previously from $33.00) on shares of Redhill Biopharma in a report on Wednesday. Zacks Investment Research raised shares of Redhill Biopharma from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a report on Tuesday, July 4th. FBR & Co reissued a “buy” rating on shares of Redhill Biopharma in a report on Friday, June 16th. Finally, UBS AG started coverage on shares of Redhill Biopharma in a report on Wednesday, September 13th. They issued a “reduce” rating for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $23.35.

Shares of Redhill Biopharma (RDHL) traded up 0.3596% during trading on Wednesday, reaching $9.9356. 67,115 shares of the company traded hands. The stock’s market capitalization is $170.52 million. Redhill Biopharma has a 12 month low of $8.16 and a 12 month high of $14.74. The company has a 50-day moving average of $8.95 and a 200-day moving average of $9.33.

Redhill Biopharma (NASDAQ:RDHL) last posted its earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The firm had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $0.34 million. Analysts forecast that Redhill Biopharma will post ($2.36) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Redhill Biopharma Ltd. (RDHL) Stock Rating Reaffirmed by Roth Capital” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/06/redhill-biopharma-ltd-rdhl-stock-rating-reaffirmed-by-roth-capital.html.

Several hedge funds have recently bought and sold shares of RDHL. Bank of New York Mellon Corp bought a new position in shares of Redhill Biopharma in the first quarter worth about $101,000. Renaissance Technologies LLC lifted its holdings in shares of Redhill Biopharma by 144.1% in the first quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after acquiring an additional 36,600 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Redhill Biopharma by 36.5% in the first quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 6,172 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Redhill Biopharma in the first quarter worth about $276,000. Finally, Family Management Corp bought a new position in shares of Redhill Biopharma in the first quarter worth about $163,000. 10.99% of the stock is owned by hedge funds and other institutional investors.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Stock Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related stocks with our FREE daily email newsletter.